… representative cases of molecular glues and analyzes the binding mode of the molecular
glue–protein complex. Based on the aggregation mode of molecular glues mediating protein–…

… The vast majority of currently marketed drugs rely on small molecules with an ‘occupancy-driven’
mechanism of action (MOA). Therefore, the efficacy of these therapeutics depends on a …

… TPD offers a new method for investigating cellular pathways and shows potential as a
promising therapeutic strategy. Most TPD strategies are based on small-molecule degraders that …

… Recent studies also suggest that inhibiting CDK2 could be a promising therapeutic strategy
to treat acute myeloid leukemia (AML) [77,78]. Despite extensive efforts put forth by both …

… (15) Recently, important progress has been made in the rational discovery or design of
molecular glue degraders, which is emerging as a promising strategy for therapeutic intervention (…

… these molecules, with a special focus on molecular glues. We also outline the advantages of
the molecular glues and … A selection of promising E3 ligase molecular glues, non-E3 ligase …

… To get the most out of this promising therapeutic modality, it is useful to think of molecular
glues … dynamic properties are a promising class of emerging drugs that can also be considered …

… emerged as a promising therapeutic field for previously undruggable protein targets. Molecular
glues and … In this review, we discuss the function and rational design of molecular glues, …

… Here we review the recently discovered molecular glues, general features and insights that
… molecular glues, and the implications for drug discovery directed towards molecular glues. …

… In summary, compound 73 is an encouraging therapy for AML and is currently undergoing
preclinical development as a pioneering targeted protein degrader designed for CD33-…